<DOC>
	<DOCNO>NCT02203851</DOCNO>
	<brief_summary>The primary objective study investigate long-term safety efficacy BI 655066/ABBV-066/risankizumab , patient moderate severe chronic plaque psoriasis , open-label treatment .</brief_summary>
	<brief_title>Extension Trial Assessing Safety Efficacy BI 655066/ABBV-066/Risankizumab Patients With Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Inclusion criterion : Patients moderate severe chronic plaque psoriasis , successfully complete precede trial , 1311.2 . Successful completion precede trial define either follow : 1 . Completion entire follow period , thus reach Endofstudy ( EOS ) visit . 2 . Loss response , define decrease response &lt; PASI50 time week 24 . Patient must give informed consent sign approve consent form prior study procedure accordance Good Clinical Practice ( GCP ) local legislation Applicable female patient : Negative urine pregnancy dip stick test rollover visit , available rollover visit , negative Serum ßHuman Chorionic Gonadotropin ( ßHCG ) test . In addition : Women childbearing potential ( surgically sterilize menarche 1. year postmenopausal ) , , sexually active agree use one appropriate medically accept method birth control addition consistent correct use condom date rollover visit 12 week last treatment trial . Medically accept method contraception : ethinyl estradiol contain contraceptive , diaphragm spermicide substance , intrauterinedevice . OR Female patient vasectomized sexual partner ( ) ( vasectomy least 1 year prior enrolment ) . OR Surgically sterilize female patient documentation prior hysterectomy , tubal ligation complete bilateral oophorectomy . OR Postmenopausal woman postmenopausal define permanent cessation &gt; = 1 year previously occur menses . Exclusion criterion : Patients experience drug relate Serious Adverse Event precede trial Patients develop guttate , erythrodermic pustular psoriasis druginduced psoriasis ( diagnosed investigator ) , precede trial 1311.2 . Evidence current previous clinically significant disease , medical condition psoriasis , find medical examination ( include vital sign electrocardiography ( ECG ) ) , opinion investigator , would compromise safety patient quality data . Known clinically important acute chronic infection include hepatitis , HIV . In regard Tuberculosis follow applies : Signs symptom suggestive current active latent tuberculosis upon medical history , physical examination and/or chest radiograph ( posterioranterior lateral view , take within 3 month prior first administration study drug read qualified radiologist ) . History latent active TB prior screen , except patient document completion adequate treatment regimen , least 6 month prior first administration study agent . Positive QuantiFERONTB Gold InTube test ( IGRA ) within 2 month prior rollover visit ( available ) , active tuberculosis rule . This apply patient history latent tuberculosis document completion adequate treatment regimen , least 6 month prior first administration study agent . Patients develop malignancy , suspicion active malignant disease precede trial 1311.2 ( except treat cutaneous squamous cell basal cell carcinoma carcinoma situ cervix adequately treat ) . Intake restrict medication drug consider likely interfere safe conduct study , assess investigator . Alcohol drug abuse within 3 month prior rollover visit would interfere trial participation ongoing condition lead decrease compliance study procedure opinion investigator . Any clinically significant laboratory abnormality base last available lab result receive preceding trial ( accord investigator 's medical assessment ) Premenopausal woman pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>BI 655066</keyword>
	<keyword>risankizumab</keyword>
</DOC>